(NASDAQ: RZLT) Rezolute's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.48%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.67%.
Rezolute's earnings in 2026 is -$84,228,000.On average, 12 Wall Street analysts forecast RZLT's earnings for 2026 to be -$74,184,845, with the lowest RZLT earnings forecast at -$82,529,684, and the highest RZLT earnings forecast at -$56,270,239. On average, 12 Wall Street analysts forecast RZLT's earnings for 2027 to be -$71,476,601, with the lowest RZLT earnings forecast at -$94,721,569, and the highest RZLT earnings forecast at -$38,183,376.
In 2028, RZLT is forecast to generate -$30,259,608 in earnings, with the lowest earnings forecast at -$60,959,425 and the highest earnings forecast at $31,149,596.